Compare PCRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | AUTL |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 596.2M |
| IPO Year | 2010 | 2025 |
| Metric | PCRX | AUTL |
|---|---|---|
| Price | $24.70 | $2.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $30.25 | $8.50 |
| AVG Volume (30 Days) | 429.3K | ★ 1.4M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $541,533,000.00 | $10,120,000.00 |
| Revenue This Year | $6.78 | $80.32 |
| Revenue Next Year | $8.54 | $53.96 |
| P/E Ratio | $130.00 | ★ N/A |
| Revenue Growth | 26.04 | ★ 496.00 |
| 52 Week Low | $18.80 | $1.18 |
| 52 Week High | $27.66 | $2.58 |
| Indicator | PCRX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 49.07 |
| Support Level | $24.61 | $1.37 |
| Resistance Level | $25.17 | $2.07 |
| Average True Range (ATR) | 0.74 | 0.09 |
| MACD | -0.10 | -0.03 |
| Stochastic Oscillator | 42.32 | 36.11 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.